Psychedelics are on the rise, and women may benefit

Co-founder Juan Pablo Cappello said: “We started the company knowing that women over 40 were three to four times as likely as men to take antidepressants, which led to a five-point One of the women takes an antidepressant to get through the day.” and CEO of Nue Life, a ketamine treatment platform that received FDA approval in April and raised $23 million.

Through platforms such as Nue Life, or at one of hundreds of ketamine treatment clinics in the United States, patients can take controlled amounts of psychoactive substances to induce a change in state of consciousness (one trip) under the careful direction of a trained clinician . Ketamine, which has gained a lot of airtime in recent years for its ability to treat PTSD, anxiety and substance abuse, is now being studied as an effective way to relieve symptoms of postpartum depression.

One A recent study In the Journal of Affective Disorders, a single dose of ketamine given before anesthesia for cesarean delivery is effective in preventing postpartum depression in patients at high risk for postpartum depression. Another ketamine therapy startup, Field Trip, is also about to begin in-person Phase I clinical trials of FT-104, a psychedelic molecule similar to psilocybin, but with a much shorter travel time. (Nikhita Singhal’s father, Sanjay Singhal, founder of Audiobooks.com, is a consultant to Field Trip.) “FT-104 has all the features that make psilocybin so interesting and appealing from a therapeutic perspective—safety and effectiveness — but the duration of the action is short,” Field Trip co-founder and executive chairman Ronan Levy told me. According to Levy, Field Trip’s existing preclinical studies show that FT-104 will leave the body after 12 hours, meaning breastfeeding can be assumed to resume within 24 hours — something that will ultimately need to be validated and accepted in human trials Scientific peer review.

Kelsey Ramsden, the former CEO of Vancouver-based psychedelic company Mindcure (which had been researching MDMA-assisted psychotherapy to help women with a lack of libido until it closed earlier this year for lack of funding), also said the postpartum depression market The development of psychedelics is being called for as there is currently only one drug available to treat the condition (Zuleso). Ramsden believed this in part because psychedelics relieved her own symptoms after she gave birth to her first child. “The changes I’ve gone through in my life have led to recurring cycles of depression, and the persistent problems aren’t necessarily hormonal,” she said. “It’s just that my experience has changed as a result of being a mother in a society that expects me to be a mother in a certain way.” She says she tried SSRIs and traditional therapy at first, but after trying psychedelic-assisted psychology After therapy, she finally got her footing.

Ramsden believes that the entire psychedelic industry is still in its infancy. But she can imagine a culture in which it’s normal for women to openly take psychedelics.when something related to health work For women, she believes, good news spreads like wildfire.

According to Allison Feduccia, who has a PhD in neuropharmacology, the best evidence on how psychedelics affect women remains largely anecdotal.For example, there are accounts that indicate Cactus boosts milk productionideas to support Preliminary research in the 1970s. Over the years, these methods have been reported Psychedelics changed their menstrual cycle, linking them to a heavier period, a period that came earlier, or—or—a more regular cycle. Studies have shown that estrogen enhances the brain’s dopamine reward pathway, so a woman’s response to a particular drug may also be more pleasurable, depending on the stage of her menstrual cycle.

Feduccia thinks psychedelics may be especially helpful for the “coming-of-age rites” that most women experience. “When you’re having your first period, having your first baby, and then going through menopause, psychedelics can bring a better perspective,” she said. “I just want women to benefit [from psychedelics] Get a guided method without spending $20,000. ”

This method of bootstrapping is not only costly, but also fraught with ethical issues. Several high-profile cases of psychedelic therapy abuse have made headlines in recent years. Richard Yensen, an unlicensed therapist and MAPS associate investigator, was accused of sexually assaulting a PTSD patient in MDMA’s MAPS clinical trial. Sexual abuse allegations were also filed against Aharon Grossbard and his wife Françoise Bourzat, leaders of a prominent Bay Area group that has been practicing psychedelic-assisted therapy for more than 30 years.

Source link